From the discovery of tubulin to the approval of vinblastine for anticancer treatment, it has been more than half a century. Microtubules play an extremely important role in cell division, and disruption of the formation of mitotic spindles affects all dividing cells. For cancer cells that proliferate faster than… Continue Reading The development of microtubule inhibitors – the big story of small molecules

  Opioids are usually the mainstay of perioperative and chronic pain, and even local pain treatment, but these drugs have many side effects, including nausea, irritations, itching, urinary retention, constipation, etc., and more serious tolerance. , addiction and the risk of overuse of death. Opioids are usually administered systemically, primarily… Continue Reading Tetrodotoxin is “tamed” and has a local analgesic effect for up to 3 days! Or an alternative to opioids

  The regulation of human blood glucose concentration is mainly achieved by the mutual restriction of insulin and glucagon at multiple levels. Among them, insulin produced by islet β cells is responsible for promoting blood glucose absorption and lowering blood glucose concentration. Islet beta cell destruction or dysfunction can lead… Continue Reading Nature’s paper: Treating diabetes with cell therapy is worth looking forward to

  Pancreatic cancer is one of the most malignant tumors. It is called “the king of cancer” because of its low survival rate and extremely short survival period. It is usually asymptomatic in the early stage and often spreads to the whole body when it is diagnosed. Pancreatic cancer is… Continue Reading Nature: The king of cancer also has weakness

  Metformin is the most widely used type 2 diabetes drug, and is known as a “magic medicine” because of its anti-cancer and anti-aging effects. Now, scientists from the University of Dundee in the UK have recently discovered that metformin can also reverse the thickening of harmful myocardial walls that… Continue Reading Metformin may reduce the risk of heart disease, the first clinical trial results in top journals

  Following the announcement on February 12 that the ASK1 inhibitor selonsertib (GS4997) missed the first-order endpoint in its first phase III clinical trial (STELLAR-4), Gilead announced on April 25 that selonsertib was in another STELLAR-3 study. The scheduled clinical endpoint of 48 weeks was not reached.   STELLAR-4 study… Continue Reading Gilead NASH new drug selonsertib second phase III clinical failure

  At the end of 2018, Celgene understated the monotherapy of CD47 monoclonal antibody CC-90002 for the treatment of acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). On the day of the suspension of the CC-90002 trial, shares in other CD47 companies such as Trillium, Forty Seven, and Surface… Continue Reading Second generation CD47 antibody: a new hot spot for tumor immunotherapy

  Metabolism involves a series of biochemical reactions that convert nutrients into metabolites that play an important role in maintaining cellular homeostasis and in response to intracellular and extracellular stimuli. Metabolic changes are one of the important features of tumors. In order to maintain sustained proliferation, tumor cells must adjust… Continue Reading The next wave of cancer immunotherapy – regulating metabolism

  On April 3, a study published in the journal Nature, scientists from Stanford University found that blocking the activity of protein CD22 with an antibody can improve cognitive behavior in aging mice. Dr. Tony Wyss-Coray, a professor of neuroscience, led the research. Dr. Wyss-Coray has been working for years… Continue Reading Is it difficult to develop Alzheimer’s disease “new drug”? This target may be a savior

  On March 7, the New England Journal of Medicine published the results of a Phase I study of BI 655139 in the treatment of generalised pustular psoriasis (GPP). Pustular psoriasis is a rare type of psoriasis, accounting for no more than 1%. It is usually divided into generalized pustular… Continue Reading Boehringer Ingelheim first in class monoclonal antibody is surprisingly effective for rare psoriasis